Trial · NCT07012044
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum tolerated dose of ASTX727 | Up to completion of cycle 2 (cycle length=28 days) | Defined as maximum dose at which fewer than one-third of patients experience dose limiting toxicity. |
| Primary | Incidence of adverse events of ASTX727 | Up to 2 years | Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
| Primary | Area under the concentration by time curve of ASTX727 | Up to 28 days | Median area under the concentration over time curve assessed at 1 and 3 hours post dose in cycle 1 stratified by dose level. |
| Primary | Half life of ASTX727 | Up to 28 days | Median half-life of ASTX727 stratified by dose level assessed at 1 and 3 hours post dose in cycle 1 stratified by dose level. |
| Primary | Clearance of ASTX727 | Up to 28 days | Median clearance of ASTX727 assessed at 1 and 3 hours post dose in cycle 1 stratified by dose level. |
| Secondary | Incidence of graft versus host disease of ASTX727 | Up to 2 years | Frequency of graft versus host disease stratified by dose level. |
| Secondary | Severity of graft versus host disease of ASTX727 | Up to 2 years | Frequency of graft versus host disease severity score stratified by dose level. |
| Secondary | Incidence of graft rejection of ASTX727 | Up to 2 years | Frequency of graft rejection stratified by dose level. |
| Secondary | Severity of graft rejection of ASTX727 | Up to 2 years | Frequency of graft rejection severity score by dose level. |
| Secondary | Event free survival of ASTX727 | At 1 year | Median time to event stratified by dose level. |
| Other | Pharmacodynamic profile of ASTX727 | At cycle 1 day 1 and cycle 1 day 8 | Assessed through deoxyribonucleic acid methylation assay. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07012044/registered